Stroke: does interrupting antiplatelet therapy raise CV risk?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Discontinuation of antiplatelet therapy is not significantly associated with increased risk for cardiovascular event in patients with acute ischemic stroke.
Why this matters
Antiplatelet therapy is recommended for long-term secondary stroke prevention, but discontinuation rates of up to 50% have been reported.
5.2% of patients with stroke and 7.5% of control patients stopped or interrupted antiplatelet therapy.
Patients who interrupted or stopped therapy had higher baseline National Institutes of Health Stroke Scale score (P<.001) and were more likely to have previous ischemic heart disease (P=.004) or stroke (P=.049) compared with persistent users.
Risk for cardiovascular event was similar in patients who stopped/interrupted therapy (OR, 0.70; P=.352) or had early cessation (OR, 1.04; P=.876) compared with persistent users.